Press Releases and News

VibroSense Dynamics AB (VibroSense) - Several positive signs from the market as the Company continues to implement its business plan.

The business plan is continuously implemented with several actions in parallel. VibroSense has carried out various market activities and supported its customers as well as partners in multiple research studies. VibroSense has also identified that there is a pronounced interest in Sweden among people living with diabetes, to pay themselves for a reliable foot examination outside the public health care system.

The diabetes clinic “Herz- und Diabeteszentrum Nordrhein-Westfalen” (HDZ NRW) evaluates the instrument VibroSense Meter ® II with a planned start on September 22, 2022.

The diabetes clinic at HDZ NRW is a top-ranked clinic at the university hospital in Bochum in Germany. For the past two years (2020 and 2022), the clinic has received the highly regarded award "5-Sterne-Auszeichnung" awarded by the institute "Bundesverband Klinischer Diabetes- Einrichtungen ” (BKvD).

The result from a clinical pilot study, in collaboration with the clinic of Oncology at the university hospitals in Lund and Malmö as well as the hospital in Kristianstad, shows that VibroSense Meter® and its technology can be used to predict the risk of getting permanent nerve damage caused by treatment of cancer with chemotherapy. The discovery is an important step to pave the way for a new biomarker that can support physicians within cancer treatment with chemotherapy.

VibroSense Dynamics AB (VibroSense) clinical validation study for the new application Diabetes Foot Screening, shows that the company's product VibroSense Meter® II meets all essential criteria for approval according to the clinical validation plan. VibroSense thus keeps the schedule the company has previously communicated and is ready to launch the Diabetes Foot Screening application to both primary and specialist care.

At the scientific congress, Humanchwingungen in Würzburg Germany on October 1 2020, the results of a pilot study were presented in which the company's product VibroSense Meter® II was used. The aim of the study was to investigate short-term effects of exposure to hand-arm vibrations. The result showed a strong impact wherein a significant decrease of the sensitivity of fingers was detected with the VibroSense Meter® II. The data will become the basis for new recommendations for health controls of vibration-exposed personnel in Germany.